Pancreatic Cancer Research

ResearcherFukushima Medical UniversityActive in the last 2 years

Hiroyuki Asama

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0102-0404; OpenAlex author ID A5077087020. Sources: OpenAlex.

Their work

Papers
17 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
23
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 4 papers · 2023: 2 papers · 2024: none · 2025: 5 papers

Papers 17

  1. Prediction model for mutation detection via circulating tumor DNA analysis in pancreatic cancer. First author DOI 10.1016/j.pan.2025.09.003↗
  2. A Systemic Review and Meta-analysis of the Incidence Rate of Interstitial Lung Disease in Patients with Unresectable Pancreatic Cancer Treated with Gemcitabine… Co-author DOI 10.2169/internalmedicine.5084-24↗
  3. Prediction System for KRAS Mutation Detection in Circulating Tumor DNA in Unresectable Pancreatic Cancer. Co-author DOI 10.21873/anticanres.17751↗
  4. Development and Validation of a Nomogram of Predict Eligibility for Second-line Chemotherapy in Pancreatic Cancer. Co-author DOI 10.21873/anticanres.17798↗
  5. Impact of COVID-19 pandemic on unresectable pancreatic cancer: a regional cohort study in Japan. First author DOI 10.5387/fms.24-00011↗
  6. Clinical benefit of subsequent chemotherapy after drug-induced interstitial lung disease in pancreatic cancer patients: a multicenter retrospective study from … Co-author DOI 10.1186/s12885-023-10781-x↗
  7. A multicenter comparative study of endoscopic ultrasound-guided fine-needle biopsy using a Franseen needle versus conventional endoscopic ultrasound-guided fin… Co-author DOI 10.5946/ce.2022.019↗
  8. Modified FOLFIRINOX versus sequential chemotherapy (FOLFIRI/FOLFOX) as a second-line treatment regimen for unresectable pancreatic cancer: A real-world analysi… Co-author DOI 10.1002/cam4.4512↗
  9. Sarcopenia: Prognostic Value for Unresectable Pancreatic Ductal Adenocarcinoma Patients Treated With Gemcitabine Plus Nab-Paclitaxel. Co-author DOI 10.1097/mpa.0000000000001985↗
  10. Prognostic significance of sarcopenia as determined by bioelectrical impedance analysis in patients with advanced pancreatic cancer receiving gemcitabine plus … Co-author DOI 10.3892/ol.2022.13495↗
  11. Drug treatment for chemotherapy-induced peripheral neuropathy in patients with pancreatic cancer. Co-author DOI 10.5387/fms.2021-32↗
  12. Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients. Co-author DOI 10.1186/s12885-021-09069-9↗
  13. An observation study of the prognostic effect of waiting times in the management of pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/ol.2018.9626↗
  14. Fibrosis-related miRNAs as serum biomarkers for pancreatic ductal adenocarcinoma. First author DOI 10.18632/oncotarget.23377↗
  15. Evaluation of inflammation-based markers for predicting the prognosis of unresectable pancreatic ductal adenocarcinoma treated with chemotherapy. Co-author DOI 10.3892/mco.2018.1696↗
  16. Contrast-enhanced harmonic endoscopic ultrasonography in gallbladder cancer and pancreatic cancer. Co-author DOI 10.5387/fms.2017-04↗
  17. Clinical significance of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2016.09.003↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hiromasa Ohira · 15 shared papers, 2016–2025 · strength 2.19
  2. Mitsuru Sugimoto · 14 shared papers, 2016–2025 · strength 2.04
  3. Rei Suzuki · 12 shared papers, 2016–2025 · strength 1.58
  4. Tadayuki J. Takagi · 12 shared papers, 2016–2025 · strength 1.56
  5. Hiroshi Shimizu · 5 shared papers, 2025 · strength 1.17
  6. Kentaro Sato · 5 shared papers, 2025 · strength 1.17
  7. Hiroki Irie · 7 shared papers, 2018–2025 · strength 1.05
  8. Rei Ohira · 4 shared papers, 2025 · strength 0.94
  9. Yuichi Waragai · 5 shared papers, 2016–2025 · strength 0.64
  10. Rei Suzuki · 2 shared papers, 2025 · strength 0.46
  11. Satoshi Kobayashi · 3 shared papers, 2022 · strength 0.42
  12. Manabu Morimoto · 3 shared papers, 2022 · strength 0.42
  13. Makoto Ueno · 3 shared papers, 2022 · strength 0.42
  14. Shin Maeda · 3 shared papers, 2022 · strength 0.42
  15. Shigeru Marubashi · 3 shared papers, 2018–2023 · strength 0.30
  16. Shuhei Nagashima · 2 shared papers, 2022 · strength 0.28
  17. Shun Tezuka · 2 shared papers, 2022 · strength 0.27
  18. Shinichi Ohkawa · 1 shared paper, 2022 · strength 0.13
  19. Yuichiro Tozuka · 1 shared paper, 2022 · strength 0.13
  20. Soichiro Morinaga · 1 shared paper, 2022 · strength 0.13
  21. Atsushi Masamune · 2 shared papers, 2016–2018 · strength 0.12
  22. Ya’an Kang · 1 shared paper, 2016 · strength 0.05
  23. Jason B. Fleming · 1 shared paper, 2016 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.